DaVita's Next Clinical Leap: Expanded HD Deployment and the New Bundle

DaVita’s Next Clinical Leap

DaVita’s second-quarter earnings call was as much about the future of dialysis as about the quarter itself. The headline numbers were reassuring—adjusted operating income of $579M, EPS of $4.02, and free cash flow of $256M—but the real narrative centered on two converging forces: the newly cleared middle molecule technology and the full integration of phosphate binder therapies into Medicare’s dialysis bundle. Together, they frame a company quietly betting that better clinical outcomes will translate into durable volume growth.

CEO Javier Rodriguez opened the call by declaring, “Our strategy is coming together.” He then highlighted the MOTheR trial results, which showed that expanded HD using a medium-cutoff dialyzer is non-inferior to HDF on a composite endpoint of mortality and major cardiovascular events.

We have secured supply to these expanded HD dialyzers, which are fully compatible with our existing machines and provide highly effective clearance of middle molecules. As a result, we expect to begin deploying expanded HD broadly across our network in the coming quarters.

This is a company-unique theme—no global competitor on the call is talking about expanded HD. The operational advantage, as Rodriguez explained, is that expanded HD runs on existing machines, meaning HD dialyzer adoption can scale without major capital outlay. CFO Joel Ackerman was careful to temper enthusiasm: “The impact is insignificant until the mortality benefit kicks in. We wouldn't expect the positive mortality impact to start until 2028.” That timeline aligns with management’s guidance to return to at least 2% treatment-volume growth by 2029.

Equally notable is the policy front. The transition of phosphate binders into the bundle has exceeded expectations. Rodriguez noted, “This has reduced by more than 50% the number of patients relying on less effective over-the-counter options such as TUMS.” CMS’s proposed 2027 rule includes a base-rate update that still trails medical cost trends, but the agency has cut its phosphate-binder spend estimate by nearly $500 million since the program began. The company supports ending the TDAPA period, viewing the policy as a win for both patients and government outlays.

Financially, the quarter reaffirmed guidance: adjusted OI midpoint of $2.2B and EPS of $14.65. Volume growth slightly exceeded expectations—treatments rose 56 bps year-over-year—but the improvement was entirely mortality-driven, offset by fewer admits from Fresenius clinic closures and higher missed treatments. Commercial mix declined sequentially, reflecting lower ACA enrollment, a $40M full-year headwind that balloons to $70M next year.

Free cash flow generation remains robust, but operating income, while up 10% year-over-year, is still shy of its 2017 peak by over 20%—the expanded HD rollout is one lever management hopes will close that gap. Leverage sits at 3.37x, within the target 3–3.5x, and the company continued its Berkshire repurchase agreement.

The stock has already reflected some optimism: DVA returned +15.8% over the last 90 days, though it is 27.9% off its late-July high. The pullback suggests investors are pricing in the 2028 mortality-timing lag that management itself flagged.

What Prior Calls Told Us

The expanded HD narrative isn’t entirely new. Prior transcripts show middle-molecule clearance was a known ambition. On the Q4 2025 call, Rodriguez said, “We will talk about the mid-molecule clearance… but back to your point, that will take time.” Yet the concrete step of securing supply and announcing broad deployment is a fresh development. More telling is the consistent clinical message: on the Q1 2026 call, he reminded investors, “It is a clinical story… mortality was improving year after year.” The company is now translating that story into a tangible technology.

What’s changed is confidence. The MOTheR data, the NIPRO approval, and the supply agreement turn a theoretical possibility into a near-term commercial rollout. That’s why the call centered on Volume growth and Commercial mix—the two dynamics that will determine whether the investment pays off.

Why It Matters

DaVita is not just riding a sector tailwind; it is creating a new niche. Expanded HD could be a differentiator as regulators push for value-based care. The phosphate-binder integration also strengthens the case that policy can align with clinical innovation. The company’s reaffirmed guidance, despite the ACA headwind, speaks to confidence in its cost structure and operating leverage.

Investors should watch the back half for the $50–100M sequential OI uplift (driven largely by IKC timing) and any signs that expanded HD adoption is ahead of schedule. If the mortality benefit indeed arrives by 2028, DaVita’s long-run volume story would look that much more credible.